HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TMO
Thermo Fisher Scientific Inc.
TMO's fundamentals are strong: it turned 16% of its revenue into free cash flow and free cash flow grew 24%. At 37x earnings, it's trading above its usual 32x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TMO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Under pressure |
TMO's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TMO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $699 | — |
| Cheap | 27x | $514 | -27% |
| Fair | 32x | $610 | -13% |
| Expensive | 37x | $708 | +1.2% |
| Current | 37x | $699 | — |
Historical ranges are pointers, not guarantees.
TMO's PE is in its expensive range at 37x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TMO Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
TMO has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TMO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.95 | +42% |
| Q3 2026 | $18.96 | +9.5% |
| Q2 2026 | $18.59 | +7.5% |
| Q1 2026 | $18.19 | +6.7% |
| Q4 2025 | $17.74 | +7.3% |
| Q3 2025 | $17.31 | +8.5% |
| Q2 2025 | $17.29 | +7.3% |
| Q1 2025 | $17.05 | +9.4% |
| Q4 2024 | $16.53 | +7% |
TMO has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TMO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TMO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.1B | +9.1% |
| Q2 2026 | $12B | +10% |
| Q1 2026 | $11B | +6.2% |
| Q4 2025 | $12.2B | +7.2% |
| Q3 2025 | $11.1B | +4.9% |
| Q2 2025 | $10.9B | +3% |
| Q1 2025 | $10.4B | +0.2% |
| Q4 2024 | $11.4B | +4.7% |
TMO's revenue has grown year over year for nine quarters in a row: $12.1B last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +1.2 points |
| Q2 2026 | 17% | +0.5 points |
| Q1 2026 | 17% | +0.4 points |
| Q4 2025 | 18% | +0.8 points |
| Q3 2025 | 17% | +0.1 points |
| Q2 2025 | 17% | -0.4 points |
| Q1 2025 | 17% | +0.5 points |
| Q4 2024 | 18% | +0.7 points |
TMO has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TMO on cash flow, with more consistent year-over-year improvement.
TMO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.1B | +15% |
| Q2 2026 | $1.7B | +52% |
| Q1 2026 | $816M | +126% |
| Q4 2025 | $3B | +6.5% |
| Q3 2025 | $1.8B | -3.1% |
| Q2 2025 | $1.1B | -33% |
| Q1 2025 | $361M | -60% |
| Q4 2024 | $2.8B | -15% |
TMO's free cash flow has been positive every quarter for seven years: $7.6B over the past year, up 24% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TMO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TMO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.9% | -7M shares |
| 3 years | -4.4% | -17M shares |
| 5 years | -6.5% | -26M shares |
| Available history | -7.9% | -32M shares |
TMO has 371M diluted shares, down 1.9% from a year ago, with $4B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $1B |
| Q1 2026 | $3B |
| Q4 2025 | $37M |
| Q3 2025 | $963M |
| Q2 2025 | — |
| Q1 2025 | $2B |
| Q4 2024 | $1B |
TMO spent $4B buying back its own shares over the past year, up 1.9% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TMO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 2.8x | Moderate |
| Q3 2025 | 3.3x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 2.6x | Moderate |
TMO's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.3 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TMO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.4 | Overbought |
| Stochastic | 86.6 | Overbought |
TMO's weekly RSI is 70 (overbought) and its Stochastic is 87 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TMO PE vs Healthcare Sector
| Metric | TMO | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 79 | 29 | 50 pts above |
TMO is trading at 37x earnings, a 43% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TMO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $680.4 | 2.8% above |
| 20 week MA | $623.9 | 12% above |
| 50 week MA | $560.3 | 25% above |
| 100 week MA | $526.4 | 33% above |
| 200 week MA | $538.4 | 30% above |
TMO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TMO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $326.6 | $458.1 | +40% |
| 2021 | $458.1 | $650.7 | +42% |
| 2022 | $650.7 | $540.7 | -17% |
| 2023 | $540.7 | $530.8 | -1.8% |
| 2024 | $530.8 | $526.1 | -0.9% |
| 2025 | $526.1 | $580.7 | +10% |
| 2026 YTD | $580.7 | $699.4 | +20% |
TMO has the edge over HIMS on returns for 2026, with the stronger performance.